Related Experiment Video

Updated: Jul 13, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in

Roy S Herbst1, Yun Oh, Asavari Wagle

  • 1M. D. Anderson Cancer Center, Houston, University of Texas, Houston, TX 77030-4009, USA. rherbst@mdanderson.org

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|August 3, 2007
PubMed

Insights

Enzastaurin, a novel protein kinase C (PKC) inhibitor, shows promise in cancer treatment by inducing apoptosis and reducing tumor growth. Its favorable safety profile supports extended use, particularly for lung cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Protein Kinase C (PKC) signaling pathways are implicated in cancer development.
  • Targeting PKC offers a potential therapeutic strategy for various malignancies.
  • Enzastaurin is an oral serine/threonine kinase inhibitor designed to target PKC-beta.

Purpose of the Study:

  • To review the rationale for targeting PKC in cancer.
  • To summarize preclinical data and clinical findings of enzastaurin.
  • To present the case for enzastaurin's evaluation in lung cancer treatment.

Main Methods:

  • Review of preclinical studies investigating enzastaurin's efficacy.
  • Analysis of Phase I and II clinical trial data for safety and preliminary efficacy.
  • Summary of enzastaurin's mechanism of action, including suppression of PKC-beta and PI3K/AKT pathways.

Main Results:

  • Enzastaurin effectively suppresses tumor cell apoptosis, proliferation, and angiogenesis.
  • Enzastaurin demonstrates a favorable safety profile, allowing for prolonged administration.
  • Preclinical and early clinical data support enzastaurin's therapeutic potential.

Conclusions:

  • Enzastaurin's mechanism of action and safety profile warrant further investigation.
  • The drug's ability to target key cancer pathways makes it a candidate for lung cancer therapy.
  • Future clinical trials are proposed to assess enzastaurin's efficacy in lung cancer patients.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...